-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Revolution Medicines, Lowers Price Target to $247

Benzinga·11/13/2026 18:05:24
Listen to the news
Morgan Stanley analyst Sean Laaman maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target from $272 to $247.